Stockholm exchange. Sector: Healthcare. Industry: Medical Instruments & Supplies. Location Sweden, Danderyd.

Ortivus AB (publ) [ORTI-A.STSweden

6USD0.05 (+0.83%)

• At close Wed Oct 05 2022

21,876,543 USD
MARKET CAP
23.437
PE
0.556
BETA (5y)
0.256
EPS

profit

125%

for 5 years

profit

81%

for 3 years

profit

22%

for 2 years

profit

19%

for 1 year

profit

8%

for this year

About Ortivus AB (publ)

Ortivus AB (publ) develops and commercializes medical technology solutions for healthcare industry in Sweden and internationally. The company offers MobiMed Monitor that monitors and measures the patient's vital parameters, such as ECG, blood pressure, and SpO2; MobiMed ePR, an electronic patient record system for documentation of treatment and events; MobiMed Life, which is designed for advanced monitoring and resuscitation; and MobiMed Cloud that supports multiplatform data sharing on Windows, Webb, IOS, and Android. It also provides support, implementation, training, and consulting services. The company was incorporated in 1985 and is headquartered in Danderyd, Sweden.

Ortivus offers innovative solutions for safe and efficient healthcare. With MobiMed, healthcare professionals can remotely measure vital parameters and gain access to advanced documentation and decision support functions, while real-time patient data is shared throughout the care chain.

Ortivus AB (publ)
https://www.ortivus.com
© 2022 avazzy.com. All rights reserved
Make with 🤎 and ☕ for you!

Investing involves risk, including possible loss of principal.

The strategies discussed are strictly for illustrative and educational purposes and are not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. There is no guarantee that any strategies discussed will be effective.

International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation and the possibility of substantial volatility due to adverse political, economic or other developments. These risks often are heightened for investments in emerging/ developing markets or in concentrations of single countries.